These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 18317884)
1. In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine. Takeda M; Tada H; Higuchi H; Kobayashi Y; Kobayashi M; Sakurai Y; Ishida T; Ohuchi N Breast Cancer; 2008; 15(2):145-52. PubMed ID: 18317884 [TBL] [Abstract][Full Text] [Related]
2. [In vivo single molecular fluorescence imaging for analysis of pharmacokinetics]. Takeda M; Gonda K; Higuchi H; Ohuchi N Gan To Kagaku Ryoho; 2008 Aug; 35(8):1277-80. PubMed ID: 18701837 [TBL] [Abstract][Full Text] [Related]
3. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model. Wu J; Ma R; Cao H; Wang Z; Jing C; Sun Y; Zhang Y; Yang Z; Hoffman RM; Tang J Anticancer Res; 2013 Feb; 33(2):419-24. PubMed ID: 23393332 [TBL] [Abstract][Full Text] [Related]
4. Multilayered, core/shell nanoprobes based on magnetic ferric oxide particles and quantum dots for multimodality imaging of breast cancer tumors. Ma Q; Nakane Y; Mori Y; Hasegawa M; Yoshioka Y; Watanabe TM; Gonda K; Ohuchi N; Jin T Biomaterials; 2012 Nov; 33(33):8486-94. PubMed ID: 22906608 [TBL] [Abstract][Full Text] [Related]
5. Nano-imaging of the lymph network structure with quantum dots. Hikage M; Gonda K; Takeda M; Kamei T; Kobayashi M; Kumasaka M; Watanabe M; Satomi S; Ohuchi N Nanotechnology; 2010 May; 21(18):185103. PubMed ID: 20388975 [TBL] [Abstract][Full Text] [Related]
6. In vivo imaging of quantum dots. Texier I; Josser V Methods Mol Biol; 2009; 544():393-406. PubMed ID: 19488714 [TBL] [Abstract][Full Text] [Related]
7. Fluorescence nanoparticles "quantum dots" as drug delivery system and their toxicity: a review. Ghaderi S; Ramesh B; Seifalian AM J Drug Target; 2011 Aug; 19(7):475-86. PubMed ID: 20964619 [TBL] [Abstract][Full Text] [Related]
9. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice. Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607 [TBL] [Abstract][Full Text] [Related]
10. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model. Orlova A; Wållberg H; Stone-Elander S; Tolmachev V J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403 [TBL] [Abstract][Full Text] [Related]
11. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Steinhauser I; Spänkuch B; Strebhardt K; Langer K Biomaterials; 2006 Oct; 27(28):4975-83. PubMed ID: 16757022 [TBL] [Abstract][Full Text] [Related]
12. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264 [TBL] [Abstract][Full Text] [Related]
13. Targeting her-2/neu with antirat Neu virosomes for cancer therapy. Waelti E; Wegmann N; Schwaninger R; Wetterwald A; Wingenfeld C; Rothen-Rutishauser B; Gimmi CD Cancer Res; 2002 Jan; 62(2):437-44. PubMed ID: 11809693 [TBL] [Abstract][Full Text] [Related]
14. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697 [TBL] [Abstract][Full Text] [Related]
15. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
16. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053 [TBL] [Abstract][Full Text] [Related]
17. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Lu RM; Chang YL; Chen MS; Wu HC Biomaterials; 2011 Apr; 32(12):3265-74. PubMed ID: 21306768 [TBL] [Abstract][Full Text] [Related]
18. Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Tan YF; Chandrasekharan P; Maity D; Yong CX; Chuang KH; Zhao Y; Wang S; Ding J; Feng SS Biomaterials; 2011 Apr; 32(11):2969-78. PubMed ID: 21257200 [TBL] [Abstract][Full Text] [Related]
19. Quantum dots for cancer diagnosis and therapy: biological and clinical perspectives. Zhang H; Yee D; Wang C Nanomedicine (Lond); 2008 Feb; 3(1):83-91. PubMed ID: 18393668 [TBL] [Abstract][Full Text] [Related]
20. Multicolor core/shell silica nanoparticles for in vivo and ex vivo imaging. Rampazzo E; Boschi F; Bonacchi S; Juris R; Montalti M; Zaccheroni N; Prodi L; Calderan L; Rossi B; Becchi S; Sbarbati A Nanoscale; 2012 Feb; 4(3):824-30. PubMed ID: 22159192 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]